Stock Scorecard



Stock Summary for AlloVir Inc (ALVR) - $0.55 as of 11/20/2024 7:43:21 PM EST

Total Score

13 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ALVR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ALVR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ALVR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ALVR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ALVR (24 out of 90)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for ALVR

$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of IPXX, YOTA, IVCP and ALVR 11/15/2024 11:10:00 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, EMKR, STAF, ALVR on Behalf of Shareholders - Adams Resources & Energy ( AMEX:AE ) , AlloVir ( NASDAQ:ALVR ) 11/12/2024 9:54:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AlloVir, Inc. ( Nasdaq - ALVR ) , EMCORE Corporation ( Nasdaq - EMKR ) , Staffing 360 Solutions, Inc. ( Nasdaq - STAF ) , Adams Resources & Energy, Inc. ( NYSE American - AE ) 11/12/2024 8:43:00 PM
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. - ALVR 11/8/2024 5:29:00 PM
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina 11/8/2024 11:00:00 AM
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina - AlloVir ( NASDAQ:ALVR ) 11/8/2024 11:00:00 AM
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm - AlloVir ( NASDAQ:ALVR ) 9/16/2024 3:16:00 PM
BK Virus Infection Market to Witness Surge in Growth During the Study Period ( 2020-2034 ) | DelveInsight 7/4/2024 9:31:00 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR - AlloVir ( NASDAQ:ALVR ) 3/23/2024 6:01:00 PM
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - AlloVir ( NASDAQ:ALVR ) 3/19/2024 2:15:00 PM

Financial Details for ALVR

Company Overview

Ticker ALVR
Company Name AlloVir Inc
Country USA
Description Allovir, Inc., a clinical-stage cell therapy company, is dedicated to the research and development of ready-to-use, multi-virus-specific allogeneic T-cell therapies (TSVs) to prevent and treat devastating virus-associated diseases. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 0.55
Price 4 Years Ago 38.44
Last Day Price Updated 11/20/2024 7:43:21 PM EST
Last Day Volume 223,343
Average Daily Volume 419,129
52-Week High 2.48
52-Week Low 0.52
Last Price to 52 Week Low 5.77%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -3.49
Free Cash Flow Ratio 0.52
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 86.78
Total Cash Per Share 1.06
Book Value Per Share Most Recent Quarter 1.06
Price to Book Ratio 0.53
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 115,365,000
Market Capitalization 63,450,750
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -12.87%
Reported EPS 12 Trailing Months -0.90
Reported EPS Past Year -0.31
Reported EPS Prior Year -1.67
Net Income Twelve Trailing Months -100,197,000
Net Income Past Year -190,418,000
Net Income Prior Year -168,710,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 121,900,000
Total Cash Past Year 183,900,000
Total Cash Prior Year 233,800,000
Net Cash Position Most Recent Quarter 121,900,000
Net Cash Position Past Year 183,900,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 145,781,000
Total Stockholder Equity Prior Year 224,519,000
Total Stockholder Equity Most Recent Quarter 121,118,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -94,873,000
Free Cash Flow Per Share Twelve Trailing Months -0.82
Free Cash Flow Past Year 0
Free Cash Flow Prior Year -142,156,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.06
MACD Signal -0.02
20-Day Bollinger Lower Band 0.59
20-Day Bollinger Middle Band 0.76
20-Day Bollinger Upper Band 0.92
Beta 0.74
RSI 38.67
50-Day SMA 0.81
150-Day SMA 3.79
200-Day SMA 8.82

System

Modified 11/20/2024 5:16:47 PM EST